First clinical application of accelerator-based boron neutron capture therapy outside of

首次在加速器基础的硼中子俘获疗法的临床应用

Asia

亚洲

Ongoing clinical trial is enrolling patients with inoperable, locally recurrent head and neck cancer

正在进行的临床试验正在招募无法手术、局部复发的头颈癌患者。

HELSINKI

赫尔辛基

and

和

BOSTON

波士顿

,

，

May 16, 2025

2025年5月16日

/PRNewswire/ -- Neutron Therapeutics LLC and the

/PRNewswire/ -- Neutron Therapeutics LLC和

Helsinki University

赫尔辛基大学

Hospital announce that they have treated the first cancer patients in a European hospital with accelerator-based boron neutron capture therapy (BNCT). This milestone marks the culmination of a multi-year collaborative effort and represents the first clinical application of accelerator-based BNCT in the west..

医院宣布，他们已经在欧洲的一家医院使用基于加速器的硼中子俘获疗法（BNCT）治疗了首批癌症患者。这一里程碑标志着多年合作努力的结晶，并代表了基于加速器的BNCT在西方的首次临床应用。

Approved in

批准于

Japan

日本

but not currently available to patients outside of

但目前无法提供给患者以外的人

Asia

亚洲

, BNCT is a tumor-targeted radiation therapy in which epithermal neutrons activate a boron-bearing compound that is selectively taken up by tumors. The boron-neutron reaction generates high-energy alpha particles within tumor cells, destroying them while sparing healthy tissues. In contrast to treatments like traditional radiation or chemotherapy, BNCT is administered in just one or two sessions and has the potential to deliver highly effective radiation therapy at the cellular level while causing minimal disruption to patient quality of life..

，BNCT是一种肿瘤靶向放射疗法，其中热中子激活一种被肿瘤选择性摄取的含硼化合物。硼-中子反应在肿瘤细胞内产生高能α粒子，摧毁肿瘤细胞的同时保护健康组织。与传统放疗或化疗不同，BNCT仅需一到两次治疗即可实施，并且有潜力在细胞层面提供高效放射治疗，同时对患者生活质量的影响降到最低。

The patients treated are the first in a ten-patient study aimed at demonstrating the safety of BNCT for locally recurrent head and neck cancer using Neutron Therapeutics' nuBeam

接受治疗的患者是十名患者研究中的第一批，该研究旨在证明使用中子治疗公司的nuBeam进行硼中子俘获疗法（BNCT）对局部复发的头颈癌的安全性。

®

®

device, a compact accelerator-based, high-throughput neutron source used in combination with a locally compounded boron-carrying drug. The Comprehensive Cancer Center at

设备，一种紧凑型加速器基高通量中子源，与局部复配的含硼药物结合使用。综合癌症中心 tại

Helsinki University

赫尔辛基大学

Hospital has served as a hub for BNCT research and clinical trials since 1992 and is the first European facility to house a nuBeam

医院自 1992 年以来一直是 BNCT 研究和临床试验的中心，并且是第一个拥有 nuBeam 的欧洲设施。

®

®

Suite.

套房。

Neutron Therapeutics' nuBeam

中子治疗公司的nuBeam

®

®

Suite includes the complete array of tools required to administer BNCT: a neutron source, patient positioning & imaging capabilities, treatment control software, and treatment planning software. Clinical validation of the nuBeam

套件包括管理BNCT所需的所有工具：中子源、患者定位和成像功能、治疗控制软件以及治疗规划软件。nuBeam的临床验证

®

®

Suite is ongoing and the company intends to submit for a CE mark when complete. Neutron Therapeutics is also in discussions with academic medical centers in

套件正在进行中，公司打算在完成后提交CE标志申请。Neutron Therapeutics还正在与学术医疗中心进行讨论。

the United States

美国

to bring this innovative cancer therapy to American patients.

将这种创新的癌症疗法带给美国患者。

'Neutron Therapeutics is proud to help bring BNCT to the western world, where no one has received this promising treatment for many years due to the decommissioning of reactor-based BNCT facilities,' said

“中子治疗公司很自豪能够帮助将硼中子俘获疗法（BNCT）引入西方世界，由于基于反应堆的BNCT设施已经停止使用，多年来没有人接受过这种有前景的治疗，”

Bill Buckley

比尔·巴克利

, co-founder of Neutron Therapeutics. 'We look to a future where BNCT may be an alternative for patients whose disease does not respond to conventional forms of treatment. We are grateful to partner with the clinical team at

Neutron Therapeutics联合创始人表示：“我们展望未来，BNCT可能成为那些对传统治疗方法无反应的患者的替代选择。我们很感激能与临床团队合作。”

Helsinki University

赫尔辛基大学

Hospital, who bring decades of clinical experience to this endeavor.'

医院，他们为这项工作带来了数十年的临床经验。'

'We are excited to take this first clinical step towards making BNCT available to the people of

“我们很高兴朝着将BNCT提供给民众迈出了第一个临床步骤，

Finland

芬兰

and ultimately

最终

Europe

欧洲

and beyond,' said

“以及更远的地方，”

Johanna Mattson

约翰娜·马特森

, Director of the Comprehensive Cancer Center at

，综合癌症中心的主任

Helsinki University

赫尔辛基大学

Hospital. 'This clinical trial addresses an area of significant unmet need. Our hospital's experience with BNCT makes us well positioned to carry out this study and the subsequent trials that we hope will bring this therapy to many more patients with different types of solid tumors.'

医院。 “这项临床试验针对的是一个存在重大未满足需求的领域。我们医院在BNCT方面的经验使我们能够很好地开展这项研究，以及我们希望将这种疗法带给更多不同类型的实体瘤患者的后续试验。”

About

关于

Helsinki University

赫尔辛基大学

Hospital

医院

Helsinki University

赫尔辛基大学

Hospital

医院

is a pioneer in the clinical use of BNCT. Using a research nuclear reactor as the neutron source, the hospital has applied BNCT to over 200 cancer patients. With Neutron Therapeutics nuBeam

是BNCT临床应用的先驱。该医院使用研究型核反应堆作为中子源，已将BNCT应用于200多名癌症患者。借助Neutron Therapeutics的nuBeam

®

®

Suite,

套房，

Helsinki University

赫尔辛基大学

Hospital will continue its leadership in developing clinical applications for many cancer indications and become

医院将继续其在开发多种癌症适应症的临床应用方面的领导地位，并成为

Europe's

欧洲的

first accelerator-based BNCT practitioner.

第一个基于加速器的BNCT实践者。

About Neutron Therapeutics

关于中子治疗公司

Neutron Therapeutics

中子治疗公司

is a leading provider of boron neutron capture therapy (BNCT) systems for use in the radiation treatment of cancer patients. Neutron Therapeutics' flagship product, the nuBeam

是用于癌症患者放射治疗的硼中子俘获疗法 (BNCT) 系统的领先提供商。中子治疗公司的旗舰产品 nuBeam

®

®

therapy platform, is an accelerator-based, in-hospital neutron source to replace the previously required nuclear reactor. nuBeam

治疗平台，是一个基于加速器的医院中子源，用于取代之前所需的核反应堆。nuBeam

®

®

has the highest flux of all BNCT systems and provides superior beam quality according to guidelines established by the IAEA for the clinical use of neutrons.

在所有BNCT系统中具有最高的通量，并根据IAEA为中子临床使用制定的指南提供卓越的束流质量。

Contact:

联系：

inquiries@nt-bnct.com

inquiries@nt-bnct.com

SOURCE Neutron Therapeutics

来源：中子治疗公司

WANT YOUR COMPANY'S NEWS

希望贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

是否在PRNEWSWIRE.COM上展示？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用